S&P 500   3,948.28 (+0.81%)
DOW   32,216.73 (+1.11%)
QQQ   304.77 (-0.19%)
AAPL   157.34 (+1.51%)
MSFT   270.64 (-3.15%)
META   197.47 (+0.95%)
GOOGL   101.19 (-0.42%)
AMZN   97.02 (-1.95%)
TSLA   183.10 (+1.65%)
NVDA   258.05 (+0.31%)
NIO   8.69 (+5.21%)
BABA   80.74 (-1.14%)
AMD   96.15 (-1.73%)
T   18.44 (+1.71%)
F   11.19 (-0.97%)
MU   57.14 (+0.85%)
CGC   1.87 (-6.50%)
GE   89.61 (-0.75%)
DIS   93.72 (+0.56%)
AMC   4.30 (+2.87%)
PFE   40.59 (+1.22%)
PYPL   72.70 (-0.40%)
NFLX   303.72 (+0.07%)
S&P 500   3,948.28 (+0.81%)
DOW   32,216.73 (+1.11%)
QQQ   304.77 (-0.19%)
AAPL   157.34 (+1.51%)
MSFT   270.64 (-3.15%)
META   197.47 (+0.95%)
GOOGL   101.19 (-0.42%)
AMZN   97.02 (-1.95%)
TSLA   183.10 (+1.65%)
NVDA   258.05 (+0.31%)
NIO   8.69 (+5.21%)
BABA   80.74 (-1.14%)
AMD   96.15 (-1.73%)
T   18.44 (+1.71%)
F   11.19 (-0.97%)
MU   57.14 (+0.85%)
CGC   1.87 (-6.50%)
GE   89.61 (-0.75%)
DIS   93.72 (+0.56%)
AMC   4.30 (+2.87%)
PFE   40.59 (+1.22%)
PYPL   72.70 (-0.40%)
NFLX   303.72 (+0.07%)
S&P 500   3,948.28 (+0.81%)
DOW   32,216.73 (+1.11%)
QQQ   304.77 (-0.19%)
AAPL   157.34 (+1.51%)
MSFT   270.64 (-3.15%)
META   197.47 (+0.95%)
GOOGL   101.19 (-0.42%)
AMZN   97.02 (-1.95%)
TSLA   183.10 (+1.65%)
NVDA   258.05 (+0.31%)
NIO   8.69 (+5.21%)
BABA   80.74 (-1.14%)
AMD   96.15 (-1.73%)
T   18.44 (+1.71%)
F   11.19 (-0.97%)
MU   57.14 (+0.85%)
CGC   1.87 (-6.50%)
GE   89.61 (-0.75%)
DIS   93.72 (+0.56%)
AMC   4.30 (+2.87%)
PFE   40.59 (+1.22%)
PYPL   72.70 (-0.40%)
NFLX   303.72 (+0.07%)
S&P 500   3,948.28 (+0.81%)
DOW   32,216.73 (+1.11%)
QQQ   304.77 (-0.19%)
AAPL   157.34 (+1.51%)
MSFT   270.64 (-3.15%)
META   197.47 (+0.95%)
GOOGL   101.19 (-0.42%)
AMZN   97.02 (-1.95%)
TSLA   183.10 (+1.65%)
NVDA   258.05 (+0.31%)
NIO   8.69 (+5.21%)
BABA   80.74 (-1.14%)
AMD   96.15 (-1.73%)
T   18.44 (+1.71%)
F   11.19 (-0.97%)
MU   57.14 (+0.85%)
CGC   1.87 (-6.50%)
GE   89.61 (-0.75%)
DIS   93.72 (+0.56%)
AMC   4.30 (+2.87%)
PFE   40.59 (+1.22%)
PYPL   72.70 (-0.40%)
NFLX   303.72 (+0.07%)
NYSE:NHWK

NightHawk Biosciences - NHWK Stock Forecast, Price & News

$0.93
+0.03 (+2.89%)
(As of 03/20/2023 02:34 PM ET)
Add
Compare
Today's Range
$0.88
▼
$0.94
50-Day Range
$0.88
▼
$1.24
52-Week Range
$0.75
▼
$3.42
Volume
26,610 shs
Average Volume
43,356 shs
Market Capitalization
$23.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

NightHawk Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($0.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.38 out of 5 stars

Medical Sector

983rd out of 983 stocks

Pharmaceutical Preparations Industry

480th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

NHWK stock logo

About NightHawk Biosciences (NYSE:NHWK) Stock

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Receive NHWK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NHWK Stock News Headlines

December 12, 2022 | finance.yahoo.com
NHWK: Shifting Focus to Biomanufacturing
November 15, 2022 | finance.yahoo.com
NightHawk Biosciences Provides Third Quarter 2022 Business Update
March 20, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
October 25, 2022 | bizjournals.com
New VelocityTX biomanufacturer increases jobs target as new production facility nears completion
October 21, 2022 | technews.tmcnet.com
Nighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
October 21, 2022 | finance.yahoo.com
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
October 14, 2022 | reuters.com
NightHawk Biosciences Inc
August 24, 2022 | bizjournals.com
Morrisville drugmaker building biosafety facility as part of strategy shift
March 20, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
August 23, 2022 | finance.yahoo.com
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
August 17, 2022 | finance.yahoo.com
NHWK: Scorpion Grand Opening 3Q:22
August 10, 2022 | finance.yahoo.com
NightHawk Biosciences Provides Second Quarter 2022 Business Update
July 7, 2022 | benzinga.com
NightHawk Biosciences (AMEX:NHWK), Analyst Ratings, Price Targets, Predictions
June 15, 2022 | thestreet.com
NightHawk Biosciences Inc.
June 14, 2022 | seekingalpha.com
NHWK NightHawk Biosciences, Inc.
June 13, 2022 | finance.yahoo.com
NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
June 13, 2022 | finance.yahoo.com
NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
June 5, 2022 | nasdaq.com
NightHawk Biosciences, Inc. Common Stock (NHWK)
May 18, 2022 | finance.yahoo.com
NHWK: Name Change and New Facility
May 16, 2022 | seekingalpha.com
NightHawk Biosciences GAAP EPS of -$0.32 beats by $0.17
May 16, 2022 | finance.yahoo.com
NightHawk Biosciences Provides First Quarter 2022 Business Update
May 14, 2022 | investing.com
Nighthawk Biosciences Inc (NHWK)
May 3, 2022 | seekingalpha.com
Heat Biologics completes name change to NightHawk Biosciences
May 3, 2022 | finance.yahoo.com
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
April 27, 2022 | finance.yahoo.com
Morrisville drugmaker scores $6M deal with Canada for anthrax treatment
April 27, 2022 | seekingalpha.com
Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthim
April 27, 2022 | finance.yahoo.com
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
See More Headlines
Receive NHWK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NHWK Company Calendar

Last Earnings
11/09/2021
Today
3/20/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:NHWK
CUSIP
N/A
CIK
1476963
Web
www.nighthawkbio.com
Phone
N/A
Fax
N/A
Employees
39
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+788.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,070,000.00
Net Margins
-648.44%
Pretax Margin
-658.18%
Return on Equity
-45.24%
Return on Assets
-36.70%

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
4.60
Quick Ratio
4.60

Sales & Book Value

Annual Sales
$2.11 million
Price / Sales
10.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.41 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
25,660,000
Free Float
23,326,000
Market Cap
$23.09 million
Optionable
Not Optionable
Beta
0.57

Social Links


Key Executives

  • Mr. Jeffrey Alan Wolf J.D. (Age 60)
    Founder, Chairman, CEO & Pres
    Comp: $1.31M
  • Mr. William L. Ostrander (Age 55)
    CFO & Sec.
    Comp: $371.07k
  • Dr. Justin Stebbing FRCP
    FRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
  • Colonel George E. Peoples Jr.
    F.A.C.S., FACS, M.D., Chief Medical Advisor
  • Dr. Anthony M. Manning Ph.D. (Age 61)
    Chief Scientific Advisor
  • Dr. Paul W. Tebbey M.B.A.
    Ph.D., Sr. VP of Product Devel. & Portfolio Strategy

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













NHWK Stock - Frequently Asked Questions

Should I buy or sell NightHawk Biosciences stock right now?

0 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NightHawk Biosciences in the last twelve months. There are currently for the stock. The consensus among Wall Street research analysts is that investors should "n/a" NHWK shares.
View NHWK analyst ratings or view top-rated stocks.

What is NightHawk Biosciences' stock price forecast for 2023?

0 equities research analysts have issued twelve-month price targets for NightHawk Biosciences' shares. Their NHWK share price forecasts range from $10,000,000.00 to $0.00. On average, they expect the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for NHWK or view top-rated stocks among Wall Street analysts.

How have NHWK shares performed in 2023?

NightHawk Biosciences' stock was trading at $0.8051 at the beginning of the year. Since then, NHWK shares have increased by 11.8% and is now trading at $0.90.
View the best growth stocks for 2023 here.

When is NightHawk Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our NHWK earnings forecast.

How were NightHawk Biosciences' earnings last quarter?

NightHawk Biosciences, Inc. (NYSE:NHWK) posted its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company earned $0.50 million during the quarter, compared to the consensus estimate of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 45.24% and a negative net margin of 648.44%.

When did NightHawk Biosciences' stock split?

NightHawk Biosciences's stock reverse split on the morning of Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What is NightHawk Biosciences' stock symbol?

NightHawk Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "NHWK."

Who are NightHawk Biosciences' major shareholders?

NightHawk Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.28%), Millennium Management LLC (0.26%), Virtu Financial LLC (0.26%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Edward B Smith III and John K A Prendergast.
View institutional ownership trends.

How do I buy shares of NightHawk Biosciences?

Shares of NHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NightHawk Biosciences' stock price today?

One share of NHWK stock can currently be purchased for approximately $0.90.

How much money does NightHawk Biosciences make?

NightHawk Biosciences (NYSE:NHWK) has a market capitalization of $23.09 million and generates $2.11 million in revenue each year. The biopharmaceutical company earns $-35,070,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How can I contact NightHawk Biosciences?

NightHawk Biosciences' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The official website for the company is www.nighthawkbio.com. The biopharmaceutical company can be reached via email at investorrelations@heatbio.com.

This page (NYSE:NHWK) was last updated on 3/20/2023 by MarketBeat.com Staff